Abstract
Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.
Original language | English |
---|---|
Pages (from-to) | 1122-1128 |
Number of pages | 7 |
Journal | Biochemical and Biophysical Research Communications |
Volume | 463 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2015 Jul 13 |
Bibliographical note
Funding Information:This study was supported by the National Cancer Center , Korea ( NCC-1420300 ), and by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which was funded by the Ministry of Health & Welfare of the Republic of Korea ( HI12C1280 ).
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
All Science Journal Classification (ASJC) codes
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology